Dr. Henderson launched Vybion in 2008 with a Cornell platform focused on Intrabody drug development. In 2011 Vybion collaborated with a group at Caltech and subsequently developed the first in class disease modifying Intrabody Gene Therapy for Huntington’s Disease currently in preclinical development. Lee has developed over 10 biologic drugs, has an extensive background in viral diseases as a transition into viral delivery for gene therapy. Lee has helped launch and fund several startups companies including Geneweave Biosciences. He participated as a coach and mentor in many seed workshops at multiple venues including the Cornell Incubator. Lee received a PhD from the University of South Carolina in Biochemistry in 1981 and received a postdoctoral fellowship while at the University of Texas Health Science Center in Dallas. He was a faculty member at Tulane Medical School (1984-1990) and Director of Molecular Virology for the Guthrie Research Institute (1990-1995).